Study on the effectiveness of il-6 and il-10 multiple immune markers for early liver cancer screening in high-risk populations

JIANG Qin; ZHANG Xufan; ZHANG Manli

PDF(2478 KB)

Journal of Hunan Normal University(Medical Science) ›› 2025, Vol. 22 ›› Issue (2) : 81-86.

Study on the effectiveness of il-6 and il-10 multiple immune markers for early liver cancer screening in high-risk populations

JIANG Qin¹, ZHANG Xufan², ZHANG Manli¹

Author information +

History +

Abstract

Objective This study aims to evaluate the effectiveness of the multiple immune markers interleukin (IL) -6 and IL-10 in screening for early liver cancer in high-risk populations. The study investigates their diagnostic performance to provide more precise biomarker support for early screening in high-risk individuals. Methods A total of 118 individuals who were treated or underwent physical examinations at our hospital from December 2021 to December 2022 were included in the study. Among them, 90 were high-risk for liver cancer (including 60 high-risk individuals without cancer and 30 early-stage liver cancer patients confirmed during follow-up), and 28 healthy individuals undergoing routine health checks (healthy control group). All participants underwent serum IL-6 and IL-10 level measurements by chemiluminescence immunoassay (CLIA) and were followed up regularly. The diagnostic performance of IL-6 and IL-10 was analyzed using ROC curves to determine the optimal cutoff values and assess screening indicators such as sensitivity and specificity. Results The levels of IL-6 and IL-10 in the early liver cancer group were significantly higher than those in the high-risk non-cancer group and the healthy control group. The ROC curve AUC for IL-6 and IL-10 were 0.81 and 0.86, respectively, with IL-10 showing slightly better screening performance than IL-6. When IL-6 and IL-10 markers are used in combination, the AUC increases to 0.90, the sensitivity reaches 85.7%, and the specificity is 80.0%, which is significantly better than single marker detection. Conclusion Both IL-6 and IL-10 demonstrated good diagnostic performance in high-risk populations for liver cancer. Combined detection significantly improves the effectiveness of early liver cancer screening, showing promising clinical application potential.

Key words

IL-6 / IL-10 / early liver cancer / screening effectiveness

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

JIANG Qin, ZHANG Xufan, ZHANG Manli. Study on the effectiveness of il-6 and il-10 multiple immune markers for early liver cancer screening in high-risk populations[J]. Journal of Hunan Normal University(Medical Science). 2025, 22(2): 81-86

References

[1] SINGAL G A, DAHER D, NARASIMMAN M, et al.Benefits and Harms of Hepatocellular Carcinoma Screening Outreach in Patients with Cirrhosis: A Multi-Center Randomized Clinical Trial[J]. J Natl Cancer Inst, 2024, 117(2): 262-269.
[2] FENG H G, ZHAO H K, WANG F Y, et al.mhealth-based interventions to improving liver cancer screening among high-risk populations: a study protocol for a randomized controlled trial[J]. BMC Public Health, 2024, 24(1): 2501.
[3] 徐颖洁, 刘明慧, 陈佳婧, 等. IL-6/STAT3信号通路介导索拉非尼治疗原发性肝癌耐药机制的研究进展[J]. 现代医药卫生, 2024, 40(17): 3017-3022.
[4] PERUHOVA M, CHAKAROVA B S, MITEVA G D, et al.Genetic screening of liver cancer: State of the art[J]. World J Hepatol, 2024, 16(5): 716-730.
[5] XU Y, XIA C, LI H, et al.Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study[J]. Chin Med J (Engl) 2024, 137(12): 1414-1420.
[6] 孙玉侠, 吴勉华, 孙莎莎, 等. 基于蛋白组学探讨消癌解毒方通过IL-6/TNF-α/STAT3通路抑制肝癌小鼠肿瘤生长的作用机制[J]. 中药新药与临床药理, 2023, 34(11): 1505-1513.
[7] 崔文超, 刘明远, 关宝生, 等. 常春藤皂苷元调控IL-6抑制肝癌细胞增殖的免疫机制[J]. 中国免疫学杂志, 2023, 39(09): 1864-1871.
[8] LEE YT, FUJIWARA N, YANG JD, et al.Risk stratification and early detection biomarkers for precision HCC screening[J]. Hepatology, 2023, 78(1): 319-362.
[9] 李丹, 孙玲, 黄峰. 原发性肝癌患者血清IL-17A、IL-6、IP-10水平与临床病理学特征及预后的关系[J]. 延安大学学报 (医学科学版), 2023, 21(04): 68-71.
[10] REY I, EFFENDI-YS R.Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis[J]. Med Arch, 2021,75(3):199-203.
[11] SHIYIN W, YUHANG Z, LINGJIE W, et al.Differences in influencing mechanism of clinicians' adoption behavior for liver cancer screening technology between the leading and subordinate hospitals within medical consortiums[J]. BMC Cancer, 2024, 24(1): 514.
[12] FENG H G, YUE Q Q, ZHAO H K, et al.Factors affecting the compliance of hepatocellular carcinoma screening among high-risk populations: A systematic review and meta-analysis[J]. Public health Nurs, 2024, 41(3): 476-486.
[13] Xie C, Lin L B, Deng H, et al.[Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population].[J]. Zhonghua gan zang bing za zhi, 2024, 32(2): 140-147.
[14] 刘桂梅, 李帅, 刘香香. 原发性肝癌患者介入治疗前后血清IL-10、VEGF、D-D及mi R-135水平变化及意义[J]. 实验与检验医学, 2022, 40(06): 736-739.
[15] 张小红, 李江, 张然蓉. 慢性乙肝、肝硬化及肝癌患者Treg细胞、IL-10、IL-12表达水平及临床意义[J]. 海南医学, 2022, 33(15): 1921-1924.
[16] 张永珍. 血清中细胞因子TNF-α、IL-10、TGF-β1的水平在肝癌患者中的表达意义[J]. 罕少疾病杂志, 2022, 29(08): 53-54.
[17] 蒋锐沅. 敷和备化方联合TACE术治疗原发性肝癌临床疗效及对血清CHI3L1、IL-6、IL-8等炎症因子影响的观察[D]. 南宁: 广西中医药大学, 2021.
[18] 张璋. 2009~2015年厦门市原发性肝癌的发病、死亡和生存分析及IL-10基因单核苷酸多态性与慢性HBV感染的相关性研究[D]. 厦门: 厦门大学, 2020.